The global immunohematology market size reached US$ 1.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.4 Billion by 2027, exhibiting a growth rate (CAGR) of 4.97% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Immunohematology refers to a branch of medical sciences that studies blood and blood-forming tissues in relation to the immune system. It is used to study the presence of antigens in the blood and their reaction with antibodies that can either cause hemolysis or red blood cell (RBC) agglutination. Various immunohematology tests are conducted to ensure safe blood transfusion and prevent undesired immunity-, transplant-, and pregnancy-related reactions, and to diagnose blood related disorders and diseases such as HIV, Hepatitis, etc. They utilize various chemicals and devices, such as reagents, and automatic and semi-automatic analyzers that are based on the technology of microplates, biochips, gel cards, polymerase chain reaction and erythrocyte-magnetized technology (EMT).

The increasing prevalence of leukemia and other hematological disorders across the globe is one of the key factors driving the growth of the market. Furthermore, improvements in the healthcare infrastructure and the development of blood banks and trauma centers, especially in developing countries, is also providing a boost to the market growth. Increasing awareness among the masses regarding the activities associated with blood collection, processing, testing and storage has further created a positive impact on the demand for immunohematology devices. Additionally, various technological advancements, such as the development of innovative transfusion systems and fully-automated devices, are acting as other growth-inducing factors. These next-generation immunohematology devices aid in enhancing the efficacy of the diagnosis, minimizing analysis time and risk of human error, and providing emergency assistance to the patients. Other factors, including an increasing number of blood donation camps and awareness programs, along with improvements in the healthcare infrastructure, are projected to drive the market further.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunohematology market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, technology, application and end-user.

Breakup by Product:

Analyzing Systems
Reagents and Consumables

Breakup by Technology:

Biochips
Gel Cards
Microplates
Polymerase Chain Reaction
Erythrocyte-Magnetized Technology (EMT)
Others

Breakup by Application:

Blood-Related Diseases
HIV
Hepatitis
Blood Transfusion
Others

Breakup by End-User:

Hospitals
Blood Banks
Diagnostic Laboratories
Others

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott, Antisel, BD (Becton Dickinson and Company), Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Grifols S.A., Merck KGaA, MTC Invitro Diagnostics AG, Ortho-Clinical Diagnostics Inc (The Carlyle Group), Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., etc.

Key questions answered in this report:
How has the global immunohematology market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global immunohematology market?
What is the breakup of the market based on the product?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global immunohematology market and who are the key players?
What is the degree of competition in the industry?